Compare AOD & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AOD | NVAX |
|---|---|---|
| Founded | 2006 | 1987 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 970.0M | 1.1B |
| IPO Year | N/A | 1995 |
| Metric | AOD | NVAX |
|---|---|---|
| Price | $9.62 | $6.65 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $10.78 |
| AVG Volume (30 Days) | 423.5K | ★ 4.2M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 12.95% | N/A |
| EPS Growth | ★ 213.63 | N/A |
| EPS | 1.93 | ★ 2.07 |
| Revenue | $72,962,082.00 | ★ $1,064,651,000.00 |
| Revenue This Year | N/A | $58.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.44 | ★ $3.19 |
| Revenue Growth | N/A | ★ 20.27 |
| 52 Week Low | $6.99 | $5.01 |
| 52 Week High | $9.14 | $11.55 |
| Indicator | AOD | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 59.37 | 38.44 |
| Support Level | $9.19 | $6.20 |
| Resistance Level | $9.67 | $7.03 |
| Average True Range (ATR) | 0.11 | 0.27 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 89.69 | 35.32 |
Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.